{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacodynamics&page=9",
    "query": {
      "intervention": "Pharmacodynamics",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 3444,
    "total_pages": 345,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacodynamics&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacodynamics&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T11:46:29.218Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02561962",
      "title": "A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "AMG 224",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2015-11-20",
      "completion_date": "2022-04-21",
      "has_results": true,
      "last_update_posted_date": "2024-02-01",
      "last_synced_at": "2026-11-15T11:46:29.218Z",
      "location_count": 4,
      "location_summary": "West Hollywood, California • Boston, Massachusetts • New York, New York + 1 more",
      "locations": [
        {
          "city": "West Hollywood",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02561962"
    },
    {
      "nct_id": "NCT03656510",
      "title": "Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "JNJ-53718678",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "28 Days",
        "maximum_age": "3 Years",
        "sex": "ALL",
        "summary": "28 Days to 3 Years"
      },
      "enrollment_count": 246,
      "start_date": "2018-11-29",
      "completion_date": "2022-04-18",
      "has_results": true,
      "last_update_posted_date": "2025-02-04",
      "last_synced_at": "2026-11-15T11:46:29.218Z",
      "location_count": 14,
      "location_summary": "Madera, California • Ventura, California • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Blackfoot",
          "state": "Idaho"
        },
        {
          "city": "Nampa",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03656510"
    },
    {
      "nct_id": "NCT05533697",
      "title": "Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "mRNA-4359",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 361,
      "start_date": "2022-09-01",
      "completion_date": "2032-02-18",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-11-15T11:46:29.218Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05533697"
    },
    {
      "nct_id": "NCT03192345",
      "title": "A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Solid Tumor"
      ],
      "interventions": [
        {
          "name": "SAR439459",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cemiplimab REGN2810",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 161,
      "start_date": "2017-06-09",
      "completion_date": "2022-01-17",
      "has_results": false,
      "last_update_posted_date": "2024-08-07",
      "last_synced_at": "2026-11-15T11:46:29.218Z",
      "location_count": 6,
      "location_summary": "Fairway, Kansas • Boston, Massachusetts • Durham, North Carolina + 2 more",
      "locations": [
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03192345"
    },
    {
      "nct_id": "NCT03235219",
      "title": "A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "JNJ-64565111",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 39,
      "start_date": "2017-08-01",
      "completion_date": "2018-02-19",
      "has_results": false,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-11-15T11:46:29.218Z",
      "location_count": 2,
      "location_summary": "Chula Vista, California • Miami, Florida",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03235219"
    },
    {
      "nct_id": "NCT01993875",
      "title": "Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Idiopathic Constipation"
      ],
      "interventions": [
        {
          "name": "Lubiprostone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mallinckrodt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 164,
      "start_date": "2013-10",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2019-12-13",
      "last_synced_at": "2026-11-15T11:46:29.218Z",
      "location_count": 11,
      "location_summary": "Anniston, Alabama • Anaheim, California • DeLand, Florida + 8 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01993875"
    },
    {
      "nct_id": "NCT01039636",
      "title": "Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Transfusional Iron Overload",
        "Beta-thalassemia"
      ],
      "interventions": [
        {
          "name": "FBS0701",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "FerroKin BioSciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2009-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-02-10",
      "last_synced_at": "2026-11-15T11:46:29.218Z",
      "location_count": 3,
      "location_summary": "Oakland, California • Boston, Massachusetts • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01039636"
    },
    {
      "nct_id": "NCT07897799",
      "title": "The METAMAX Study: MT027 Allogeneic CAR-T for Brain Metastases From Advanced Solid Tumors",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain Metastases From Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "T-MAXIMUM Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 40,
      "start_date": "2027-12-30",
      "completion_date": "2030-12-20",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-11-15T11:46:29.218Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07897799"
    },
    {
      "nct_id": "NCT05039099",
      "title": "A Study to Evaluate, Safety, Tolerability, and PK of AP-101 in Participants With ALS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "AP-101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AL-S Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 73,
      "start_date": "2021-09-02",
      "completion_date": "2025-08-13",
      "has_results": true,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-11-15T11:46:29.218Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05039099"
    },
    {
      "nct_id": "NCT00227032",
      "title": "Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2005-09",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2012-03-06",
      "last_synced_at": "2026-11-15T11:46:29.218Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00227032"
    }
  ]
}